Diflunisal in osteoarthrosis of the hip and knee.
Diflunisal (750 mg per day) has been compared with acetylsalicylic acid (ASA) (3000 mg per day) in the treatment of osteoarthrosis of the hip and knee in a double-blind, randomised, multicentre, outpatient study. Thirty-one patients entered the diflunisal group and 29 the ASA group. The response of the 2 groups was comparable, but the incidence of side effects was higher in the ASA group. At the end of the 12-week period more patients in the diflunisal group chose to remain in a further, open study.
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006621:Hip Joint; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin